Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The hematopoietic-specific transcription factor p45/
NF-E2
is an important
transcriptional activator
in the erythroid and megakaryocytic lineages. We describe the first in vivo evidence for the interaction between p45/
NF-E2
and the E3 ubiquitin ligase Itch, and the subsequent ubiquitination of p45/
NF-E2
by Itch. Interestingly, Itch suppressed the transactivation activity of p45/
NF-E2
by adding a Lys63-linked polyubiquitin chain. Confocal microscopy revealed that ubiquitinated p45/
NF-E2
became localized in the cytoplasm when Itch was over-expressed. Thus, Itch-mediated ubiquitination of p45/
NF-E2
does not target the protein for proteasomal degradation, but instead retains p45/
NF-E2
in the cytoplasm, where it cannot function as a transactivator. Finally, we suggest that this Itch-dependent p45/
NF-E2
ubiquitination mechanism may regulate
NF-E2
function during the development of hematopoietic cell lineages.
...
PMID:Itch regulates p45/NF-E2 in vivo by Lys63-linked ubiquitination. 1871 48
Identification of cell type-specific enhancers is important for understanding the regulation of programs controlling cellular development and differentiation. Enhancers are typically marked by the co-
transcriptional activator
protein p300 or by groups of cell-expressed transcription factors. We hypothesized that a unique set of enhancers regulates gene expression in human erythroid cells, a highly specialized cell type evolved to provide adequate amounts of oxygen throughout the body. Using chromatin immunoprecipitation followed by massively parallel sequencing, genome-wide maps of candidate enhancers were constructed for p300 and four transcription factors, GATA1,
NF-E2
, KLF1, and SCL, using primary human erythroid cells. These data were combined with gene expression analyses, and candidate enhancers were identified. Consistent with their predicted function as candidate enhancers, there was statistically significant enrichment of p300 and combinations of co-localizing erythroid transcription factors within 1-50 kb of the transcriptional start site (TSS) of genes highly expressed in erythroid cells. Candidate enhancers were also enriched near genes with known erythroid cell function or phenotype. Candidate enhancers exhibited moderate conservation with mouse and minimal conservation with nonplacental vertebrates. Candidate enhancers were mapped to a set of erythroid-associated, biologically relevant, SNPs from the genome-wide association studies (GWAS) catalogue of NHGRI, National Institutes of Health. Fourteen candidate enhancers, representing 10 genetic loci, mapped to sites associated with biologically relevant erythroid traits. Fragments from these loci directed statistically significant expression in reporter gene assays. Identification of enhancers in human erythroid cells will allow a better understanding of erythroid cell development, differentiation, structure, and function and provide insights into inherited and acquired hematologic disease.
...
PMID:Identification of biologically relevant enhancers in human erythroid cells. 2334 46
Nuclear factor- (erythroid-derived 2) like 2 (NFE2L2, NRF2) is a key
transcriptional activator
of the antioxidant response pathway and is closely related to erythroid transcription factor
NFE2
. Under oxidative stress, NRF2 heterodimerizes with small Maf proteins and binds cis-acting enhancer sequences found near oxidative stress response genes. Using the dietary isothiocyanate sulforaphane (SFN) to activate NRF2, chromatin immunoprecipitation sequencing (ChIP-seq) identified several hundred novel NRF2-mediated targets beyond its role in oxidative stress. Activated NRF2 bound the antioxidant response element (ARE) in promoters of several known and novel target genes involved in iron homeostasis and heme metabolism, including known targets FTL and FTH1, as well as novel binding in the globin locus control region. Five novel NRF2 target genes were chosen for followup: AMBP, ABCB6, FECH, HRG-1 (SLC48A1), and TBXAS1. SFN-induced gene expression in erythroid K562 and lymphoid cells were compared for each target gene. NRF2 silencing showed reduced expression in lymphoid, lung, and hepatic cells. Furthermore, stable knockdown of NRF2 negative regulator KEAP1 in K562 cells resulted in increased NQO1, AMBP, and TBXAS1 expression.
NFE2
binding sites in K562 cells revealed similar binding profiles as lymphoid NRF2 sites in all potential NRF2 candidates supporting a role for NRF2 in heme metabolism and erythropoiesis.
...
PMID:Novel hematopoietic target genes in the NRF2-mediated transcriptional pathway. 2376 48
<< Previous
1
2